Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
E: jfletcher@lilly.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
47,000
Stocks News & Analysis
markets
June 2025 US stock market outlook: Has the storm passed?
Be wary of the recent complacency; there’s turbulent water ahead before the skies clear.
markets
US stock market outlook: Where we see opportunities in Q2
A bear market in AI stocks leads to more attractive valuations.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,796.00 | 23.70 | -0.27% |
| CAC 40 | 7,775.90 | 28.43 | -0.36% |
| DAX 40 | 23,948.90 | 38.66 | -0.16% |
| Dow JONES (US) | 42,865.77 | 1.10 | -0.00% |
| FTSE 100 | 8,864.35 | 11.27 | 0.13% |
| HKSE | 24,147.83 | 219.11 | -0.90% |
| NASDAQ | 19,615.88 | 99.11 | -0.50% |
| Nikkei 225 | 38,181.31 | 239.88 | -0.62% |
| NZX 50 Index | 12,649.10 | 43.17 | 0.34% |
| S&P 500 | 6,022.24 | 16.57 | -0.27% |
| S&P/ASX 200 | 8,565.10 | 27.00 | -0.31% |
| SSE Composite Index | 3,403.35 | 1.04 | 0.03% |